US2017095500A1PendingUtilityA1

Use of nadh or salt thereof in preparation of drugs or health-care products for treating phenylketonuria

44
Assignee: BONTAC BIO-ENGINEERING (SHENZHEN) CO LTDPriority: Nov 14, 2014Filed: Nov 13, 2015Published: Apr 6, 2017
Est. expiryNov 14, 2034(~8.3 yrs left)· nominal 20-yr term from priority
Inventors:Rongzhao FuQi ZhangYuemei Liu
A61K 9/28A61K 31/7084A23V 2002/00A61K 9/20A61K 31/7076A61P 25/28
44
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed is use of nicotinamide adenine dinucleotide (NADH) or a salt thereof in the preparation of drugs or health-care products for treating phenylketonuria (PKU), wherein a single dose of the NADH or a salt thereof is 1-100 mg.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . Use of NADH or a salt thereof in the preparation of drugs or health-care products for treating phenylketonuria (PKU), wherein the NADH or a salt thereof is used in the preparation of drugs for treating PKU. 
     
     
         2 . The use of NADH or a salt thereof in the preparation of drugs for treating PKU according to  claim 1 , wherein a single dose of the NADH or a salt thereof is 1-100 mg. 
     
     
         3 . The use of NADH or a salt thereof in the preparation of drugs for treating PKU according to  claim 2 , wherein a single dose of the NADH or a salt thereof is 1-30 mg. 
     
     
         4 . The use of NADH or a salt thereof in the preparation of drugs for treating PKU according to  claim 1 , wherein the drug or health-care product is in the form of tablets, capsules, granules, aqueous solutions, enteric-coated preparations or injections. 
     
     
         5 . The use of NADH or a salt thereof in the preparation of drugs for treating PKU according to  claim 4 , wherein the drug or health-care product is in the form of tablets. 
     
     
         6 . The use of NADH or a salt thereof in the preparation of drugs for treating PKU according to  claim 5 , wherein the tablets are enteric-coated tablets. 
     
     
         7 . The use of NADH or a salt thereof in the preparation of drugs for treating PKU according to  claim 1 , wherein the NADH is reduced NADH.

Join the waitlist — get patent alerts

Track US2017095500A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.